Joseph Sullivan, MD

Joseph Sullivan, MD, provides an overview of the recent approval of fenfluramine oral solution for the treatment of Dravet syndrome.

Elaine C. Wirrell, MD, provides an overview of cannabidiol oral solution for treatment of seizures associated with Dravet syndrome.

Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss the management of seizures for Dravet syndrome with different approved therapies.

Experts discuss the goals of treatment of patients with Dravet syndrome regarding seizure freedom and seizure burden.

Elaine Wirrell, MD, reviews the transition of care into adulthood of patients with Dravet syndrome and how this transition can affect the patient, caregiver, and care provider.

The panel discusses the impact on the family, siblings, or caregivers of patients with Dravet syndrome.

Considerations of genetic testing regarding family planning as well as behavioral issues associated with Dravet syndrome.

Elaine C. Wirrell, MD, explains the increased risk of sudden unexpected death in epilepsy (SUDEP) in patients with Dravet syndrome and how to talk about it with caregivers and families.

Elaine Wirrell, MD, provides background on fenfluramine, results from 2 clinical trials, and compares it to other treatment therapies.

Elizabeth Thiele, MD, PhD, reviews cannabidiol oral solution as treatment of seizures associated with Dravet syndrome and the safety profile and dosing associated with it.

The importance of early diagnosis of Dravet syndrome as well as seizure triggers and comorbidities are discussed by key opinion leaders in the field.

Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss the presentation of Dravet syndrome in children.

Experts in the field discuss second- and third-line treatment options for Dravet syndrome such as stiripentol and vagal nerve stimulation and the effects they’ve seen on patients.

A panel discussion on the North American Consensus statement on treating Dravet syndrome and the approved therapies like clobazam, ketogenic diets, and other first- and second-line therapies.

A discussion on having conversations with the parents of patients with Dravet syndrome with regards to adjustments to therapy and managing their expectations.

A panel of experts discuss treatment goals for patients with Dravet syndrome and how to convey the variability of treatment to the parents of these patients.

Trevor J. Resnick, MD, and Elaine Wirrell, MD, explain why the early diagnosis of Dravet syndrome is important, which patient profiles should be noted for ordering genetic testing, and what to do with those results.  

Elizabeth Thiele, MD, PhD, and Elaine Wirrell, MD, provide an overview of Dravet syndrome and the seizure triggers in pediatric patients.

The professor of neurology and pediatrics and director of the Pediatric Epilepsy Center at the University of California, San Francisco, discussed his personal experience with fenfluramine and the advantages that the drug may present when treating patients with Dravet syndrome.

The director of the Pediatric Epilepsy Center at UCSF Benioff Children’s Hospital discussed the findings and the importance of discovering more about mechanisms of action.

The Director of the Pediatric Epilepsy Center at UCSF Benioff Children's Hospital spoke about what defines a "clinically meaningful change in seizure frequency" using data from a phase 3 clinical trial of ZX008 for the adjunctive treatment of seizures associated with Dravet syndrome.